BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211101
DTEND;VALUE=DATE:20211104
DTSTAMP:20260515T204228
CREATED:20210720T100504Z
LAST-MODIFIED:20210720T100504Z
UID:31015-1635724800-1635983999@www.pharmajournalist.com
SUMMARY:5th Antifibrotic Drug Development Summit - AFDD
DESCRIPTION:The 5th Antifibrotic Drug Development Summit will provide a unique opportunity to gain cross-discipline actionable insights into how the latest scientific research is being applied to fibrosis pipeline progress. Network with industry pioneers in hot areas of drug development\, specifically IPF\, NASH\, scleroderma\, IBD\, ILD\, CKD\, and more to apply disease-specific lessons agnostically\, and understand how the industry can achieve the crowning glory of pan-fibrosis antifibrotic drugs. \nUnmissable Highlights for 2021:  \n\nJoin the active discussion surrounding redefining approvable clinical endpoints with the FDA to enhance opportunities for creative clinical trial design and drive your clinical development\nEngage with early initiatives to establish clinical development programs in IBD-associated fibrosis with Cleveland Clinic to kickstart your intestinal fibrosis pipeline as this grows in interest for biopharma\nInvestigate the buzz around reprogramming epithelial cells to promote tissue repair in fibrotic disorders with Genentech to understand new strategies for regenerative medicine and overcome mechanistic bottlenecks\nGain vital insights from Pfizer on how the industry can revolutionize the translatability of current disease models and collaboratively guide the creation of technologies that can better mimic human physiology\nEmbrace more successful clinical trial design with an enhanced focus on patient-reported outcomes with Novartis to identify precision medicine approaches\, promote patient engagement\, and discuss regulatory barriers to novel endpoints\n\nHear from 35+ industry heavyweights including Genentech\, AstraZeneca\, FDA\, GSK\, Boehringer Ingelheim\, Pfizer\, Takeda\, and more to understand transformative mechanistic strategies for promoting tissue regeneration and repair\, discover more robust predictive models to improve translatability; and assess emerging non-invasive biomarkers that identify early signs of efficacy and drive successful clinical trials. \nTo know more visit: https://ter.li/afddpjel
URL:https://www.pharmajournalist.com/event/5th-antifibrotic-drug-development-summit-afdd/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211102
DTEND;VALUE=DATE:20211105
DTSTAMP:20260515T204228
CREATED:20210823T081823Z
LAST-MODIFIED:20210823T081930Z
UID:31388-1635811200-1636070399@www.pharmajournalist.com
SUMMARY:Gastrointestinal Cancer Drug Development Summit
DESCRIPTION:The Gastrointestinal Cancer Drug Development Summit is the only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies\, ADCs\, and precision oncology to address the large unmet clinical need in GI cancers. \n**This meeting is free-to-attend for drug developers\, research institutions\, and not-for-profit organizations**. \nRegister free to attend here: https://ter.li/t83wdr    \nThis industry-dedicated meeting offers a comprehensive insight into developing optimal clinical programs for targeted\, immune\, and ADC therapies in these solid tumors. Join us and our 39+ expert speaker faculty as we navigate cancer heterogeneity and develop biomarker-driven enrichment strategies to direct better treatments to specific patient subsets and invest in rationale therapeutic combination approaches for this vastly unmet clinical need. \nWhether your group is targeting microsatellite instable (MSI) and stable (MSS) CRC\, a rare GI malignancy or treatment-resistant HCC\, this unique forum is your opportunity to establish clinical collaborations\, plan new combinatorial studies and assess how a future drug candidate can change the clinical landscape. \nExplore the full conference guide here: https://ter.li/9m9m8u \n**A “drug developer” or “researcher” must have a pipeline candidate and/or work for an academic institution\, and must not provide solutions or services for a fee to any other company. All bookings under the drug developer/researcher category are subject to organizer approval.
URL:https://www.pharmajournalist.com/event/gastrointestinal-cancer-drug-development-summit/
LOCATION:Digital Event | EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211103
DTEND;VALUE=DATE:20211105
DTSTAMP:20260515T204228
CREATED:20210813T151459Z
LAST-MODIFIED:20210813T151459Z
UID:31349-1635897600-1636070399@www.pharmajournalist.com
SUMMARY:2nd Applied Biocatalysis Summit
DESCRIPTION:Understanding the most recent developments in enzyme-catalyzed processes\, computational technologies\, and cutting-edge methodologies in biocatalytic cascade reactions is key to help the API and chemical industries apply biocatalysis more effectively. \nSpecifically designed alongside experts in the field\, this conference will delve into the key technology\, enzyme design\, manufacturing\, and scale-up challenges that must be overcome to achieve the commercial promise of biocatalysis. \nJoin us online for 2 days of insightful content\, live Q&As\, and 2+ hours of networking\, as we bring together medication developers\, chemical manufacturers\, agriculturists\, and researchers working on the complex and difficult development of biocatalyst technology. \nThis is your comprehensive virtual guide to defining your commercial potential of implementing biocatalysis methods in 2021. \nTo know more visit: https://ter.li/s09i3k
URL:https://www.pharmajournalist.com/event/2nd-applied-biocatalysis-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211108
DTEND;VALUE=DATE:20211111
DTSTAMP:20260515T204228
CREATED:20210902T200827Z
LAST-MODIFIED:20210902T200827Z
UID:31541-1636329600-1636588799@www.pharmajournalist.com
SUMMARY:LEAP TA Life Sciences
DESCRIPTION:LEAP TA: Life Sciences is a unique open platform for the boldest talent leaders in the industry to engage in genuinely disruptive dialogues. Meet 80+ of your peers to rethink your recruitment approach\, allowing you to find better people faster in an increasingly competitive talent market. \nTaking part in this live online event will help you redefine your processes in an uncertain world\, and successfully navigate the new normal operating environment. \nThis is your opportunity to fill the gap between reading an article and hiring an external consultant to help you solve your own recruitment challenges for the short\, medium\, and long term. \nTo know more visit: https://ter.li/od0sc4
URL:https://www.pharmajournalist.com/event/leap-ta-life-sciences/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211109
DTEND;VALUE=DATE:20211111
DTSTAMP:20260515T204228
CREATED:20210820T074956Z
LAST-MODIFIED:20210820T074956Z
UID:31376-1636416000-1636588799@www.pharmajournalist.com
SUMMARY:Biomarkers for Rare Diseases Summit
DESCRIPTION:As reports predict the global biomarker test market will exceed $16bn in coming years\, the ability to identify and utilize predictive\, diagnostic and prognostic biomarkers is a priority for drug developers. In rare disease\, affecting over 400 million worldwide and where clinical insights exist for only around 400 of the 7000+ disease identified\, biomarkers are a valuable tool to accelerate drug development where there is current great unmet need. With this\, we are excited to announce the launch of the inaugural Biomarkers for Rare Diseases Summit. \n \nUniting world leaders developing novel therapeutics for rare disease\, we will discuss learnings\, challenges and future directions at the only summit dedicated to approaches to identify\, test and proof clinical biomarkers in rare disease for regulatory approval. From identifying disease driving biomarkers\, robust assay validation\, harnessing latest technologies and demonstrating therapy efficacy\, we bring you the definitive platform to accelerate bench to bedside rare disease development towards regulatory filing and patient populations. \nTo Know more visit: https://bit.ly/3AX0FIt
URL:https://www.pharmajournalist.com/event/biomarkers-for-rare-diseases-summit/
LOCATION:Digital
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211115
DTEND;VALUE=DATE:20211117
DTSTAMP:20260515T204228
CREATED:20210608T113322Z
LAST-MODIFIED:20210608T113525Z
UID:30480-1636934400-1637107199@www.pharmajournalist.com
SUMMARY:Medical Devices and IVD conference 2021
DESCRIPTION:Navigating new legislations and strategies to comply with regulatory requirements \nSMi is proud to announce the launch of their Medical Devices and IVD conference to be held in London in November 2021. \nThe MDR and IVDR updates will have a profound impact on the medical device industry\, bringing certain products into regulatory scope that were previously excluded\, introducing new manufacturing requirements\, and increasing the burden for post-market surveillance. What does this mean for the future of the Medical Devices and IVD industry? \nSMi’s inaugural Medical Devices and IVD conference will provide insight into the latest updates in EU MDR and IVDR regulations and will discuss strategies for how to best comply with these new regulations. In addition\, the conference will examine MHRA Guidance on Post-Brexit IVD Regulations and consider the evolving regulatory landscape for digital health software. Join Europe’s leading Medical Device and IVD Conference which will address post-market surveillance and vigilance\, clinical evaluations and investigations\, medical device regulatory affairs in global markets\, and much more. \n \nBENEFITS OF ATTENDING: \n\nEngage with notified body and competent authority representatives addressing key MDR and IVDR requirements\nGain insights from pharma regulatory experts in compliance and companion diagnostics\nUnderstand the latest guidance on Post-Brexit IVD Regulations to overcome common challenges\, in addition to considering evolving global regulations\nExamine post-market expectations for surveillance and vigilance of your medical devices\nDelve into how COVID-19 has impacted the MDR and IVD regulations\n\nView the full agenda and speaker line-up online: www.medicaldevices-ivd.com/pjwl \nPlus\, post-conference workshop will be taking place on 17th November in London: \nImplementing the EU MDR and Article 117\, An Industry Perspective \nWorkshop Leader: Blake Green\, Senior Manager Regulatory Affairs\, Amgen \nEARLY-BIRD RATES: \n\nBOOK BY 30TH JUNE AND SAVE £200\nBOOK BY 30TH SEPTEMBER AND SAVE £100\n\nRegistrations can be made on the event website at: www.medicaldevices-ivd.com/pjwl \nCHAIR FOR 2021: \nAndreas Stange\, Vice President\, TÜV SÜD \nHEAR FROM EXPERT INDUSTRY SPEAKERS: \n\nJessica Wilkerson\, Cyber Policy Advisor\, FDA\nSusan Neadle\, Executive Director\, Combination Products\, Devices\, Diagnostics & Digital Health Regulatory Affairs\, Amgen\nClaudia Dollins\, Head\, Precision Medicine & Companion Diagnostics\, Bristol Myers Squibb\nMichael Benecky\, Senior Director\, Global Regulatory Affairs\, UCB Biosciences\nChristophe Driesmans\, Head of the Materiovigilance Entity\, Federal Agency for Medicines and Health Products (FAMHP)\nMelanie Donguy\, Head Regulatory Affairs EMEA\, Bayer Radiology\nMarc Moal\, Head of Product Delivery & Project Management\, Merck Connected Health & Devices\nJim Leamon\, Director of Biologics Device Development\, Jazz Pharmaceuticals\nLouise Place\, Director\, Devices\, GlaxoSmithkline\nStefan Strasser\, Head of Department\, Austrian Medicines and Medical Devices Agency
URL:https://www.pharmajournalist.com/event/medical-devices-and-ivd-conference-2021/
LOCATION:London\, UK | Virtual Attendance Option Available
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211116
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T204228
CREATED:20210809T105337Z
LAST-MODIFIED:20210809T105337Z
UID:31259-1637020800-1637279999@www.pharmajournalist.com
SUMMARY:5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases
DESCRIPTION:In the unprecedented array\, and steady stream of novel\, topical\, and systemic agents entering various phases of drug development\, for critical inflammatory and autoimmune dermatological conditions this year\, the 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases\, returns to Boston for 2021. As the world’s leading\, and only forum committed to overcoming significant R&D hurdles\, and sharing of best practices for advancing efficacious next generation therapies for chronic inflammatory skin conditions\, this forum is not to be missed. \nWith the rising demand for consolidation and precision medicine\, along with multiple new agents edging closer to market for Atopic Dermatitis towards the end of the year\, the 5th annual meeting addresses advances and challenges in genetic discoveries\, antibody drug development\, delivery strategies and predictive and diagnostic technologies when developing safe and effective drugs for moderate-to-severe\, inflammatory skin conditions. \nEnsure you join this year’s 150+ expert community\, in-person\, to uncover recent studies evaluating critical inflammatory and auto-immune pathways\, gain a deeper understanding of promising biologics targeting IL-13\, IL-31\, IL-33\, whilst continuing to assess emerging efficacious targeted approaches when developing safer treatments to patients with debilitating skin diseases. Additionally\, obtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet need such as Hidradenitis Suppurativa and Vitiligo. \nLeave this year’s meeting having overcome innovative modelling challenges by gaining simulation tools/strategies to support your clinical drug development pipeline\, evaluate optimal dose and dosing regimen to support formulation changes for your approach\, whilst having debated what makes a dermatology investment most successful when advancing therapies for inflammatory and autoimmune skin conditions to market. \nTo find out more visit: https://ter.li/e93ads
URL:https://www.pharmajournalist.com/event/5th-annual-dermatology-drug-development-summit-for-inflammatory-skin-diseases/
LOCATION:Hilton Boston/Woburn\, 2 Forbes Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211116
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T204228
CREATED:20210812T114547Z
LAST-MODIFIED:20210812T114547Z
UID:31287-1637020800-1637279999@www.pharmajournalist.com
SUMMARY:3rd Inflammasome Therapeutics Summit
DESCRIPTION:Discover the Intricacies of Inflammasome Regulation\, Leverage Inflammasome Proteins as Biomarkers & Accelerate Novel Inflammasome Therapeutics into Proof-Of-Concept Clinical Trials & Beyond \nBuilt with Ventus Therapeutics\, Inflammasome Therapeutics\, Merck & more\, the Inflammasome Therapeutics Summit returns for its third year as the only industry-dedicated forum to discover the intricacies of inflammasome regulation and accelerate novel inflammasome therapeutics into proof of-concept clinical trials and beyond! \nWith a plethora of inflammasome-targeted drugs poised to enter the clinic in 2021\, this year’s summit will once again unite thought leaders in inflammasome drug development. \nExpect to be involved in interactive discussions on: \n\nHow dysregulated inflammasome activation\, formation and signaling contributes to disease and how to identify novel drug targets beyond NLRP3\nThe interface of inflammasome signaling with innate immunity\, microbial interactions\, metabolism\, neuroimmune and other systems\nLeveraging inflammasome proteins in precision-based medicine as disease biomarkers and companion diagnostics in both the preclinical and clinical setting\nIdentifying and translating the most promising therapeutic applications of inflammasome-targeted drugs across monogenic diseases\, as well as infectious\, ophthalmic\, neurological and cancer settings\n\nThis year’s meeting has two parallel tracks of learning with 30+ speakers sharing highly anticipated case studies. As the growth potential of novel inflammasome therapeutics becomes apparent\, join the conversation to validate novel inflammasome targets beyond NLRP3 and realize the clinical and commercial potential of inflammasome proteins across different diseases! \nTo Know more visit: https://ter.li/bdw0tf
URL:https://www.pharmajournalist.com/event/3rd-inflammasome-therapeutics-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211116
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T204228
CREATED:20210903T051305Z
LAST-MODIFIED:20210903T051305Z
UID:31548-1637020800-1637279999@www.pharmajournalist.com
SUMMARY:3rd Exosome Based Therapeutic Development Summit
DESCRIPTION:The 3rd Exosome-Based Therapeutic Development Summit returns with a more comprehensive agenda than ever before\, reuniting leading pharma\, biotech\, technology providers and academic teams to advance therapeutically relevant exosome-based therapeutics in regenerative medicine\, autoimmunity\, COVID-19 and beyond. \nDeep diving into the key challenges such as sourcing\, characterization\, cargo loading\, manufacturing and clinical development\, this year’s summit will be your comprehensive roadmap to realizing\, strategizing and advancing the full therapeutics and drug delivery opportunities offered by exosomes. \nTailor-made to showcase the latest innovations and interactively discuss the industry’s most important talking points\, join leading biopharmaceutical Directors\, VPs and C-Level Executives to successfully optimize\, accelerate and scale your exosome-based therapeutics as next generation drugs for unmet clinical needs \nKey Highlights: \n\nShining a spotlight on orally delivered bacterial extracellular vesicles with unique pharmacological profiles with striking anti-inflammatory effects\, an exciting new approach for exosome therapeutics with Evelo Biosciences\n\n\nDeep dive into the latest data coming out of the clinic with key learnings from phase I/II trials of Covid-19\, oesteoarthirtus and gastrointestinal diseases with insights from Organicell\, University of Athens & University of Louisville\n\n\nNavigating the complex regulatory landscape for exosomes to understand what the FDA requires to progress through each development stage and the potential for successful applications into 2021 with insights from Rion\n\n\nExploring proteomic insights in understanding EVs and the mechanisms of action of EV-mediated RNA delivery to enable more efficient and efficacious exosome therapies with Exogenus Therapeutics Aruna Bio\, Stem XO & Baker Heart and Diabetes Institute\n\n\nExpanding the boundaries of engineering exosomes including cell selection\, applications of the technology\, monitoring biodistribution and enabling direct delivery with Exogenus VivaZome Therapeutics\, OmniSpriant & Exogenus Therapeutics\n\nTo know more visit: https://ter.li/h99vsb
URL:https://www.pharmajournalist.com/event/3rd-exosome-based-therapeutic-development-summit/
LOCATION:Digital Event\, EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211117
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T204228
CREATED:20210628T103640Z
LAST-MODIFIED:20210628T103640Z
UID:30747-1637107200-1637279999@www.pharmajournalist.com
SUMMARY:Wnt & β-Catenin Targeted Drug Discovery Summit
DESCRIPTION:The Wnt & β-Catenin Targeted Drug Discovery Summit is the only meeting uniting leading pharma\, pioneering biotechs and reputed academics under a mutual and ambitious objective of accelerating your novel Wnt/β-catenin candidates into clinic and market. \nBuilt with Leap Therapeutics\, Fog Pharma\, Surrozen\, Iterion Therapeutics\, Genentech\, and other leading companies\, the summit will allow you to gain knowledge on the inhibition and activation of the Wnt pathway. You can be sure to take away practical insights and actionable strategies on how to harness this previously undruggable target. \nWith 24+ expert speakers\, this is your definitive opportunity to be a part of this exciting and growing community\, and this dedicated virtual summit will ensure you get your answers to your questions. \nTo find out more and view the 2021 speaker line-up\, download the full event guide. \n \n5 unmissable keynotes include: \n\nSupercharging Your Wnt/β-catenin Clinical Program by Surrozen\, Iterion Therapeutics\, AntlarA & Leap Therapeutics\nGetting a Grip on Wnt Biology to Theorize the Latest Opportunities & Understandings with Iterion Therapeutics\, Genentech & Auburn University\nOpportunities to Aid Drug Discovery & Further Research Efforts with Biovista & the DTRF\nDelving into Immuno-Oncology to Further Oncological Treatment Efficacy\, brought to you by UAB\, Duke Cancer Institute & Shandong First Medical University\nHarnessing Novel Pathways Approach to Drive Preclinical Insights delivered by\nFog Pharma\, RedX Pharma & The University of Oxford\n\nTo know more about the Wnt & β-Catenin Targeted Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/wnt-%ce%b2-catenin-targeted-drug-discovery-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211117
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T204228
CREATED:20210708T095717Z
LAST-MODIFIED:20210708T095717Z
UID:30858-1637107200-1637279999@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Gut Therapeutics USA
DESCRIPTION:Microbiome Connect: Gut Therapeutics USA\, a two-day conference from the 17th – 18th of November 2021 and will bring you essential solutions to the challenges you face in the microbiome field. This industry-leading event will facilitate discussions concerning new clinical research\, microbiome biomarkers\, the latest regulatory developments\, gut-organ axis\, human clinical updates and much more. Hear from experts like Bernat Olle\, CEO of Vedanta Bioscience\, regarding the state of the market post-C Diff. therapy approval\, and Diwakar Davar\, to discuss his ground-breaking immuno-oncology research. \n \nThe event will have dedicated manufacturing steam; attendees will witness a showcase of solutions to scaling up your bacterial fermentation operation\, highlighting the different culturing methodologies along with discussions regarding commercialization preparation. Joined by companies such as Takeda\, Merck\, and PRI\, who will discuss the microbiome’s clinical future as a diagnostic and endpoint and examine how the industry can and should develop standardized biomarkers. Leading biotechs will discuss their latest clinical updates\, mechanistic data\, experimental methods\, and clinical trial design. \nMicrobiome Connect will be hosting their annual skin and oral event at the same venue and dates\, which all gut attendees will have access to. Download the agenda https://hubs.ly/H0RQsBQ0.
URL:https://www.pharmajournalist.com/event/microbiome-connect-gut-therapeutics-usa/
LOCATION:275 Tremont St\, Boston\, MA 02116\, United States\, MA\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211117
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T204228
CREATED:20210715T094233Z
LAST-MODIFIED:20210726T202001Z
UID:30944-1637107200-1637279999@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Oral USA
DESCRIPTION:The Oral Microbiome is the second largest and diverse microbiota in the human body\, harboring over 700 species of bacteria. A complex and constantly changing habitat\, it is crucial in maintaining not only oral health and oral diseases\, but systemic health conditions across the body. To date\, over 50 systemic diseases have been linked to an unbalanced oral microbiome\, and research in this space is accelerating. Further developing a collective understanding of the role of the oral microbiome in health and disease will allow further developments in drug development\, oral health\, and targeted therapies in the future. \nJoin us at the 6th Annual Microbiome Connect to discover the latest research relating to the oral microbiome\, and its critical and underappreciated role in human health. Be a part of the discussion surrounding pre- and pro-biotics\, innovative therapies. \nFind out more >>> https://hubs.ly/H0T0d430
URL:https://www.pharmajournalist.com/event/microbiome-connect-oral-usa/
LOCATION:Join the Microbiome Connect community at the picturesque Courtyard by Marriott\, Boston Downtown Boutique Hotel\, 275 Tremont St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211117
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T204228
CREATED:20210901T074913Z
LAST-MODIFIED:20210901T075014Z
UID:31528-1637107200-1637279999@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Skin USA
DESCRIPTION:Love the skin you’re in? How about the bugs on it? \nOver the six years we’ve run Microbiome Connect: Skin\, the field has changed drastically. In a short period\, the field has gone from fringe to mainstream\, from quantifying the size of bacterial populations to understanding their function. As the field continues to commercialize\, it is time to ask how this research can benefit consumers. How can the skin microbiome be leveraged as a source of biomarkers\, as a therapeutic modality\, as an understandable term to consumers? \nJoin us in Boston for a two-day face-to-face event\, attended in the past by the likes of P&G\, Jackson Laboratory\, and the FDA. Unravel the function of the skin microbiome and apply the latest findings to your future products. See you in November! \nTo know more visit: https://hubs.ly/H0W7lQ90
URL:https://www.pharmajournalist.com/event/microbiome-connect-skin-usa/
LOCATION:Boston\, MA\, USA
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211118
DTEND;VALUE=DATE:20211219
DTSTAMP:20260515T204228
CREATED:20211018T092817Z
LAST-MODIFIED:20211018T092817Z
UID:31844-1637193600-1639871999@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect 2021
DESCRIPTION:Virtual Expo Connect” is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals. Powered by PharmaSources.com\, Virtual Expo Connect builds an online platform to be accessed from anywhere\, adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nTo know more visit: https://bit.ly/3ASODPZ
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect-2021/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:Candice.lau@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211122
DTEND;VALUE=DATE:20211124
DTSTAMP:20260515T204228
CREATED:20200701T104907Z
LAST-MODIFIED:20200908T113552Z
UID:26139-1637539200-1637711999@www.pharmajournalist.com
SUMMARY:Ophthalmic Drugs Conference 2021
DESCRIPTION:Exploring the future of ocular drug development \nSMi proudly presents the 4th Annual Ophthalmic Drugs Conference taking place on the 22nd-23rd of November 2021\, in London. \nThe global ophthalmic drug market is forecast to surpass $60 billion USD by 2025 with increasing focus from the industry on alternative delivery approaches and improving the effectiveness of the current repertoire of drugs in order to grow away from intravitreal injections and other surgical approaches to ocular therapy. With 50% of the global population predicted to have complications in their sight within the next few decades\, ophthalmic medicine is set to become one of the biggest industries in pharmaceuticals. \n \nAs Europe’s leading Ophthalmic Drugs conference\, we will explore new discoveries in the treatment of ocular disease\, innovations in combination technologies\, and the utterly unique challenges that are faced in the treatment of one of the most complex organs in the body. \nThis two-day agenda will offer peer-to-peer networking opportunities with leaders in the ophthalmic sphere\, from Heads of Drug Development and Senior Directors of Ophthalmology\, all the way to academic forerunners in the research into ocular therapy. \nTo register or for more information visit: www.ophthalmicdrugs.com/pjwl \n BENEFITS OF ATTENDING: \n\nINSIGHT into the newest techniques in ocular drug design and delivery\nEXPLORE the impacts and applications of controlled release technologies\nLEARN how advanced medical devices are changing the face of combined therapy\nUNDERSTAND the latest developments in overcoming the challenge of treating such a complex organs\n\nWHO SHOULD ATTEND: \n\nOphthalmic Lead\nClinical Director\nSenior Medical Advisor\nFranchise Head\nBusiness Manager\nSenior Scientist\nSenior Vice President\nMedical Director\nTherapeutic Area Head\nGeneral Manager\nInternational Scientific Advisor\n\nEarly-Bird Rates \n\nBOOK BY JUNE 30TH TO SAVE £300\nBOOK BY SEPTEMBER 30TH TO SAVE £100\n\nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #OphthalmicDrugs \nLinkedIn: follow our company page – search ‘SMi Pharma’ \nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/ophthalmic-drugs-conference-2021/
LOCATION:Holiday Inn\, Kensington\, London\, UK\, London\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211129
DTEND;VALUE=DATE:20211202
DTSTAMP:20260515T204228
CREATED:20210806T084330Z
LAST-MODIFIED:20210806T084330Z
UID:31205-1638144000-1638403199@www.pharmajournalist.com
SUMMARY:5th Annual NASH Summit 2021
DESCRIPTION:Grounding the scientific data into actionable insights for drug sponsors\, the 5th NASH Summit is the outstanding forum and unrivalled platform for biotech and pharma to regroup\, reassess and realign their NASH pipeline strategy. \n \nUniting 100+ NASH experts from the EMA\, Novartis\, Gilead\, Pfizer\, Eli Lilly\, Takeda\, AstraZeneca\, Merck\, Janssen\, Ionis\, Novo Nordisk\, the FDA and more\, including stakeholders at the helm of NASH drug development and on the periphery\, this industry focused forum is bringing together content perfectly aligned with wherever you sit on prioritising NASH\, so you can continue to keep on top of this huge unmet medical need and massive opportunity for drug sponsors to scratch the pad of available\, approved\, NASH therapeutics. \nTo know more visit: https://nash-summit.com/
URL:https://www.pharmajournalist.com/event/5th-annual-nash-summit-2021/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211130
DTEND;VALUE=DATE:20211203
DTSTAMP:20260515T204228
CREATED:20210813T092849Z
LAST-MODIFIED:20210813T092849Z
UID:31293-1638230400-1638489599@www.pharmajournalist.com
SUMMARY:Cytokine-Based Cancer Immunotherapies Summit Boston
DESCRIPTION:The only in person dedicated industry forum supporting the development of robust cytokine-based cancer immunotherapy platforms (cytokine muteins\, antibody-cytokine fusion proteins (immunokines)\, anticancer vaccines\, and cancer-directed antibodies) to deliver targeted\, durable therapeutic interventions to solid tumor and hematological cancer indications. \nThis comprehensive\, drug development focused agenda will showcase the latest concepts and molecular engineering approaches being utilized by biopharma and research groups to help you overcome the challenges in: \n\nToxicity management – engineering selectivity\, targeting and half life modulation\nOptimizing the risk benefit by dose and schedule optimization\nAchieving safe and acceptable delivery\nUnderstanding the potentials for combination\nDelving into the clinical data to understand the translational side\n\nYou will have the opportunity to join a pre-conference workshop day exploring pre-clinical models for cytokine research and the world of cytokines in inflammatory disease\, providing insight into where the world of cytokine research is going beyond oncology. \nJoin this exclusive community of cytokine pioneers to network and learn from the leading experts in pharma\, biotech and academia\, as we discuss how to successfully and safely deliver cytokine therapies to a plethora of cancer indications. \nAcross 3 content packed days\, 30+ experts will converge to discuss novel cytokines\, the shortfalls of these therapies and how to learn from the pitfalls of the first cytokine era – this is not one to miss! \nTo know more visit: https://ter.li/gwz2x1
URL:https://www.pharmajournalist.com/event/cytokine-based-cancer-immunotherapies-summit-boston/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211130
DTEND;VALUE=DATE:20211203
DTSTAMP:20260515T204228
CREATED:20210820T103831Z
LAST-MODIFIED:20210820T103831Z
UID:31382-1638230400-1638489599@www.pharmajournalist.com
SUMMARY:Rare & Genetic Kidney Disease Drug Development Summit
DESCRIPTION:Marrying unmissable insights from global renal experts\, the 1st Rare & Genetic Kidney Disease Drug Development Summit is uniquely positioned to provide you with transformative perspectives from identifying genetic drivers of rare kidney diseases to innovative trial design in small disease populations to accelerate progress of your genetic kidney disease pipeline. \nHear from industry heavyweights including Sanofi Genzyme\, Alexion\, AstraZeneca\, Regulus Therapeutics\, Chinook Therapeutics\, Ionis Pharmaceuticals\, Novartis\, Otsuka Pharmaceutical Companies and many more to ignite your entry to the rare and genetic kidney disease landscape and confidently progress from proof of concept to the clinic. \nDiscover pivotal advances in disease modelling with stem cell-derived kidney organoids\, explore opportunities for comprehensive genetic diagnosis and patient stratification\, and join the conversation on progressing surrogate biomarkers and endpoints to guide strategic decisions on your pipeline in ADPKD\, Alport Syndrome and more. \nGet involved to understand why interest in rare and genetic kidney diseases is exploding and keep up to date with the latest opportunities for genetic intervention. \nTo know more visit: https://ter.li/k0fu1i
URL:https://www.pharmajournalist.com/event/rare-genetic-kidney-disease-drug-development-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211206
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T204228
CREATED:20210817T215306Z
LAST-MODIFIED:20210817T215306Z
UID:31360-1638748800-1639094399@www.pharmajournalist.com
SUMMARY:3rd Gene Therapy for Neurological Disorders
DESCRIPTION:Returning to Boston this December\, the 3rd Gene Therapy for Neurological Disorders meeting will welcome discovery\, preclinical\, translational and clinical industry scientists to share\, learn and network for the shared goal of successfully and safely delivering gene therapies to the CNS. \nWith 40+ expert leaders from the likes of Taysha Gene Therapies\, Passage Bio\, AskBio\, Neurogene\, Affinia Therapeutics and Alcyone Therapeutics sharing their progress\, don’t miss the chance to join the industry’s definitive physical conference to make new connections and reconnect with your friends and colleagues. \nOver 4 comprehensive days of networking\, presentations and discussion sessions\, this meeting will enable you to: \n\nDiscuss the latest DRG toxicity and immunogenicity research to understand the biology behind AAV toxicity in the CNS\nEvaluate current safety and toxicity strategies to navigate off target effects including redosing options\nEvaluate intraparenchymal\, intra-cisterna magna\, lumbar intrathecal and systemic delivery routes for CNS indications to assess CNS tropism and biodistribution\nHear from neurosurgeons at the forefront of delivery and explore the most up to date delivery devices to identify novel innovations and areas for development\nReview pharmacological concepts for preclinical dose selection in NHP biodistribution case studies to optimize dose extrapolation\nLearn about the different vector discovery strategies used to identify vectors with improved CNS tropism and specificity\nOptimize clinical trial design considerations for both paediatric and adult neurological patient populations to showcase efficacy to regulators and deliver value for patients\nDiscover the novel indications being targeted by gene therapies such as epilepsy\, neuropathic pain and hearing disorders to improve your knowledge of current CNS pipelines\n\nView your copy of the event guide now: https://ter.li/yrofx9
URL:https://www.pharmajournalist.com/event/3rd-gene-therapy-for-neurological-disorders/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T204228
CREATED:20210812T114045Z
LAST-MODIFIED:20210812T114045Z
UID:31282-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:iPSC-Derived Cell Therapies Summit
DESCRIPTION:Capitalize on the Scalable & Diverse Potential of iPSC-Derived Therapies By Defining Differentiation Protocols\, Optimal Cell Line Selection & Optimizing Gene Engineering To Accelerate Successfully Into the Clinic \nThe explosion of excitement and investment in the iPSC field has ushered in a new era of cell therapy\, with these cells establishing its place as the optimal starting material for cell therapies targeting cancer\, autoimmune\, cardiac disease and much more. \nThe iPSC-Derived Cell Therapies Summit is your dedicated forum exclusively focused on the common challenges across disease indications which are limiting the clinical translation of iPSC-based approaches for cell therapy\, including safety concerns with differentiation protocols\, lack of regulatory guidance\, and licensing issues. \nGet caught up to speed on this dynamic industry with expertise shared from the likes of Shoreline Biosciences\, Kite Pharma\, HeartSeed\, and Exacis\, to understand the broad applicability of iPSCs\, advances in novel gene engineering approaches\, and translational lessons learned to advance your pipeline to clinical success. \nLeave this meeting with the knowledge and connections to landscape the clinical progression\, outline GMP compliant processes for scale up\, and share strategies to ensure consistency in starting material. \nThis is your opportunity to collaborate with 80+ iPSC senior level experts from biopharma and academia and be at the forefront of the future of cell therapy by joining the mission to develop safe\, scalable and cost-effective iPSC-derived therapies. \nTo Know more visit: https://ter.li/e7gdu7
URL:https://www.pharmajournalist.com/event/ipsc-derived-cell-therapies-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T204228
CREATED:20210819T081104Z
LAST-MODIFIED:20210819T081104Z
UID:31364-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:Synthetic Biology-Based Therapeutics Summit
DESCRIPTION:Engineer ‘Intelligent’\, Controllable Drugs at the First Technical Meeting Dedicated to Advancing the Therapeutic Applications of Synthetic Biology \nThis year\, the synthetic biology market has seen fledgling companies rise to IPO smashing power players\, as the demand for high-quality\, engineered biomolecules and controllable therapeutics grows exponentially. \nThe therapeutic potential of novel synthetic units is huge\, but challenges remain in demonstrating proof-of-concept\, developing assays\, functional characterization\, manufacturing scale-up\, and identifying therapeutic applications for commercial development. \nWith an agenda curated by leaders in synthetic biology-based therapies at Synlogic\, Merck\, Bayer\, Senti Bio\, MIT and GSK\, the Synthetic Biology-Based Therapeutics Summit will provide strategic insights to deploy synthetic biology as a tool for discovery\, through to therapeutic applications. \nExplore innovations in circuit design and implementation\, harnessing the power of computation and AI to better design functioning circuits and uncover novel components which elicit therapeutic benefit. Tackle manufacturing challenges to scale up synthetic biology-based therapeutics with gold-standard quality control and characterization. \nTo Know more visit: https://ter.li/19 mj8t
URL:https://www.pharmajournalist.com/event/synthetic-biology-based-therapeutics-summit/
LOCATION:Digital | EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T204228
CREATED:20210823T104601Z
LAST-MODIFIED:20210823T104827Z
UID:31394-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:3rd Annual Targeted Radiopharmaceuticals (TRP) Summit 
DESCRIPTION:The 3rd Targeted Radiopharmaceuticals (TRP) Summit returns at a crucial time for the entire industry. Spurred on by positive Phase III VISION trial data\, there has been huge research investment\, on both sides of the Atlantic\, on how to deliver radiation therapy directly and specifically to tumours. \nFor the 2021 edition of this conference\, there will be the opportunity to attend either in-person in Berlin or remotely via a dedicated digital networking platform with all the access to the conference content. \nYou can expect a wider array of insights from recent case studies to help you accelerate the development of the next generation of radioligand therapies from clinical approval to commercialisation. \nAs the only industry-led platform for discussing challenges and opportunities facing developers of theranostic radioligand therapies\, we strive to tackle topics that are on every drug developer’s mind: \n\nHow do we identify and validate new targets?\nCan we combine Targeted Radiopharmaceuticals with immunotherapy or other targeted oncology methods?\nHow do we improve current clinical design methodologies and patient selection strategies?\nWhere can improvements be made to the current supply and fulfilment models?\n\nTo know more visit: https://ter.li/r1oll2
URL:https://www.pharmajournalist.com/event/3rd-annual-targeted-radiopharmaceuticals/
LOCATION:Berlin Germany\, & Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T204228
CREATED:20210826T090709Z
LAST-MODIFIED:20210826T090829Z
UID:31471-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:4th Commercializing Clinically Validated Digital Therapeutics Summit
DESCRIPTION:The 4th Commercializing Clinically Validated Digital Therapeutics Summit returns in December of 2021 as the only industry-led meeting deep-diving on stakeholder alliance and partnership to accelerate DTx scalability\, to enable building sustainable & viable business models. \nDTx is happening\, and happening fast on a global scale. The amount of investment continues to surge\, and is expected to reach $15\,176m in 2027. Following the pandemic\, with more emphasis on digital medicine\, telemedicine\, and decentralized clinical trials\, DTx adoption has peaked. Now is the time to join with key stakeholders across regulatory\, pricing\, physician engagement\, real world evidence\, commercial functions\, patient adherence and adoption to combat the challenges and ensure delivery of cutting edge DTx to your patients. \n \nFurthermore\, the pandemic has been the major catalyst to DTx adoption with tremendous benefits brought to patients\, physicians for treatment\, and remote clinical trials that made 2021 an inflection point for the DTx industry. \nAcross 3 days covering extensive and valuable content\, we will bring together expert speakers to share their data on case studies of lessons learnt and keys to success\, as well as insights into venturing into effective partnerships. This will give you the tools to conquer your most crucial challenges and accelerate sustainable scalability and adoption of your digital therapeutic. \nWhether you are a drug\, med device or a DTx developer\, this is your must-attend event in 2021. Hear from your peers’ journeys and lessons learned\, and re-engage in the long awaited dialogue to generate clinical and RWE\, in order to serve our patients in need beyond just a pill! \nTo know more visit: https://ter.li/cyw0ze
URL:https://www.pharmajournalist.com/event/4th-commercializing-clinically-validated-digital-therapeutics-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T204228
CREATED:20210903T051629Z
LAST-MODIFIED:20210903T133327Z
UID:31553-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:4th RNA-Targeted Drug Discovery Summit
DESCRIPTION:The 4th RNA-Targeted Drug Discovery Summit is returning once again this December\, to reunite the largest community of thought leaders and experts in biology\, chemistry and RNA therapeutics to discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity\, selectivity and drug-like properties. \nJoin the leading RNA small molecule forum alongside 150+ biopharmaceutical Directors\, VPs and C-Level Executives to hear the latest pioneering case studies and successfully translate your discovery and pre-clinical strategies into robust pipelines of RNA-targeted small molecule drugs that realize the full potential of this up-and-coming field. \nWe’re back in 2021 with a more comprehensive program than ever before & we’d love you to join us! \nKey Highlights: \n\nExpand your knowledge of the RNA landscape by gaining exclusive insights and data-driven updates to streamline the success of your RNA candidates from leaders of the field such as Nymirum\, Arrakis\, PTC Bio& Expansion Therapeutics\n\n\nOptimize and advance your RNA structural insights to guide the successful discovery & development of your RNA targeted small molecule with insights from Novartis\, AstraZeneca\, Stanford University &National Cancer Institute\n\n\nEvaluate tested & novel structure-based methods for understanding RNA-ligand interactions and binding sites alongside academic leaders Hashim Al-Hashimi\, Matthew Disney\,Amanda Garner\, Aaron Frank & Anthony Mustoe\n\n\nOvercome selectivity\, specificity & toxicity challenges and accelerate the translation of your RNA small molecule pipeline into clinical development with discussions from\nAnima Biotech\, MD Anderson Cancer Center & AstraZeneca\n\n\nDiscovery of novel chemical matter & new chemical space for small molecule intervention with insights from Roche\, University of Michigan\, Baylor College Medicine\, Remix Therapeutics\, Ladder Therapeutics &Biosplice Therapeutics\n\nTo know more visit: https://bit.ly/3mWyANC
URL:https://www.pharmajournalist.com/event/4th-rna-targeted-drug-discovery-summit/
LOCATION:Digital Event\, EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211209
DTSTAMP:20260515T204228
CREATED:20210913T100540Z
LAST-MODIFIED:20210913T100540Z
UID:31669-1638835200-1639007999@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Gut Therapeutics Europe
DESCRIPTION:Join us in Amsterdam from 7th – 8th December 2021 to find out more about why biotherapeutic products are progressing through clinics worldwide. As this trending topic gains more exposure and fast approaches commercialisation various challenges have presented themselves. Issues in areas such as key regulatory\, manufacturing and supply chain are amongst some of the themes emerging. \nCompanies such as Stellate Therapeutics\, TargEDys\, EVERIMMUNE\, Nestlé are amongst those committed to the event\, and you can reach out to them directly by securing your place. \nDownload the agenda here to view the speaker faculty and partners for 2021: https://hubs.ly/H0X0Lk_0
URL:https://www.pharmajournalist.com/event/microbiome-connect-gut-therapeutics-europe/
LOCATION:Amsterdam\, Venue TBC
ORGANIZER;CN="Hanson Wade":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T204228
CREATED:20210917T065655Z
LAST-MODIFIED:20210917T065655Z
UID:31690-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Summit
DESCRIPTION:TIGIT therapies have seen promising clinical validation\, spearheading the next wave of Immune Checkpoint Inhibitors. As such there has been an explosion of interest and high-scale investment into this exciting space. \nArriving at a critical point for TIGIT development\, the 2nd Annual TIGIT Therapies Summit is the definitive industry-led event focused at propelling this next generation inhibitor to clinical use. \nEnsure your TIGIT program reaches full clinical potential through hearing from experts about optimizing the mechanism of action\, refining Fc receptor co-engagement\, devising effective drug design\, rationalizing checkpoint combinations and utilizing biomarkers to harness the therapeutic potential of the TIGIT and DNAM-1/CD226 axes. \nJoin leaders in TIGIT development from GSK\, Gilead Sciences\, Arcus\, iTeos\, Compugen\, BeiGene\, Seattle Genetics\, Mereo BioPharma\, Harvard\, Stanford and more! \nThis event will allow you to address the key challenges associated with TIGIT therapy development and propel TIGIT to clinical use. Download the event guide to see how you can get involved.
URL:https://www.pharmajournalist.com/event/tigit-therapies-summit/
LOCATION:Digital
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211210
DTEND;VALUE=DATE:20211212
DTSTAMP:20260515T204228
CREATED:20211202T113910Z
LAST-MODIFIED:20211202T113910Z
UID:32314-1639094400-1639267199@www.pharmajournalist.com
SUMMARY:INDIAN PHARMA EXPO & BUSINESS EXCELLENCE AWARDS 2021
DESCRIPTION:Indian Pharma Expo (IPE) will provide an opportunity for the participating companies to display their products & services to the gamut of visitors\, globally from pharma and healthcare industries. The 2-day expo will bring together eminent personalities from various sectors of pharma\, non-pharma and healthcare industries. IPE is one stop juncture to all those who are planning to expand their business through various channels of franchise and distribution; as well as wholesalers and hospital purchase personnels who seek to buy bulk products on concessional rates. \n The Indian Pharma Expo will also showcase the latest trend and technologies in the pharmaceuticals\, drugs and formulations. The Expo is expected to witness approx. 10\,000 visitor’s footfall displays of latest pharmaceutical machinery\, packaging equipments\, software technology for pharma industry and management and more. Direct access to highly targeted senior pharma executives\, buyers\, procurement managers\, contract manufacturers and hospital administration. Multiple meetings will be held with managers and business development managers who are looking for new supplies\, building strategic partnerships or entering into new ventures. The Expo will feature international-cum-pharma machinery pavilion. The Expo aimed at bringing together all the pharma professionals under one roof\, the pharmaceutical exhibition focused on knowledge\, technology and business development.
URL:https://www.pharmajournalist.com/event/indian-pharma-expo-business-excellence-awards-2021/
LOCATION:Hall 12 A\, Pragati Maidan\, New Delhi\, New Delhi\, 110001\, India
ORGANIZER;CN="CIMS Medica":MAILTO:anisha.n@cims.co.in
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220112
DTEND;VALUE=DATE:20220114
DTSTAMP:20260515T204228
CREATED:20211021T082933Z
LAST-MODIFIED:20211214T010209Z
UID:31857-1641945600-1642118399@www.pharmajournalist.com
SUMMARY:SMi's Pre-Filled Syringes and Injectable Drug Devices
DESCRIPTION:SMi’s Pre-Filled Syringes and Injectable Drug Devices \n12th January to 13th January 2022\,\nVirtual Conference: Online Access Only\nConference: 12 – 13 January 2022\nFocus Day: 11 January 2022\nLocation: Virtual Conference: Online Access Only\nWebsite: http://pre-filled-syringes.com/pharmajournalist/WL \nSponsored by: BD Medical – Pharmaceutical Systems\, Crux\, Nemera\, Zeon Europe GmbH \nChaired by: \nBjørg Kaae Hunter\, Department Manager\, RA CMC & Device; RA NextGen Drug-Device\, Novo Nordisk and Daniel Latham\, Head Connected Health Product Development\, Novartis \nThe Future of Drug Delivery and Combination Product Device Design \nThe pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics\, high concentration\, and large-volume drug products. This year’s conference will explore the exciting advances in the combination product delivery space including insights into how the industry is adapting to the delayed EU MDR\, takeaways from the global pandemic and a future outlook exploring how pharma\, device developers and regulators can work together to encourage innovation. Part of the leading injectables series of events\, SMi’s 14th annual conference will bring you the key insights you need to grow and enhance your pre-filled syringes portfolio and discover what the future holds for the PFS and combination products industry. \n#PFSSMi \nKey Reasons to Attend: \n\nEngage with industry leaders on the key takeaways from the pandemic and how this can be applied to future accelerated development\nExplore updates to drug device combination product design approaches putting the user first with industry case studies from big pharma\nAssess the current landscape of device delivery mechanisms and how industry can work together to promote innovation\nUnderstand the landscape of delivery for novel drug products\, fragile molecules and long acting injectables in the interactive panel discussion\n\nDownload the brochure at: http://pre-filled-syringes.com/pharmajournalist/WL \nWho Should Attend? \nDrug-delivery developers\, Medical Device Engineers\, Primary Packaging material designers\, Secondary packagers\, Smart device developers\, Training device developers\, Device-safety solution providers\, Drug developers
URL:https://www.pharmajournalist.com/event/smis-pre-filled-syringes-and-injectable-drug-devices/
LOCATION:Virtual Conference: Online Access Only
ORGANIZER;CN="SMi Group Ltd":MAILTO:RJones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220117
DTEND;VALUE=DATE:20220119
DTSTAMP:20260515T204228
CREATED:20210920T085620Z
LAST-MODIFIED:20211217T131548Z
UID:31698-1642377600-1642550399@www.pharmajournalist.com
SUMMARY:SMi’s 10th Annual Pharmaceutical Microbiology UK Conference
DESCRIPTION:SMi’s 10th Annual Pharmaceutical Microbiology UK Conference  \nConference: 17 – 18 January 2022\nWorkshops: 19 January 2022 \nLocation: Virtual Conference: Online Access Only  \nWebsite: http://www.pharma-microbiology.com/PJwl \nSponsored by: CTL-MAT\, Ecolab and Microgenetics \nChaired by: Di Morris\, Clinical Auditor\, AstraZeneca \nExploring Robust Risk-Based Microbiological Control Strategy \nSMi’s flagship microbiology conference is celebrating its 10 year anniversary. The conference taking place on 17 and 18 January 2021 in London\, UK will bring together microbiology industry experts. \nMicrobiology remains an essential tool for the detection of microorganisms present in biopharmaceutical and pharmaceutical batches. The two-day conference will explore the most pressing topics in this thriving field\, from the movement toward process automation and minimisation of operator intervention\, to the latest technologies in rapid microbiological testing methods and data integrity. \n#SMiPharmaMicroUK \nKey Reasons to Attend: \n\nDiscover case studies in establishing holistic Contamination Control Strategies and Real-Time Viable Air Particle Counting with leaders in the pharmaceutical industry\nGain insight the current state of Endotoxin testing\, including alternative test methods and strategic approaches to method validation\nExplore the best practice in data integrity and the automation of environmental monitoring in the Microbiology Quality Control Lab\nJoin the important panel discussion on diversity and inclusion in the workplace with an experienced line-up of speakers\nDiscuss the latest developments in the detailed\, rapid detection of microbes in pharmaceutical water\n\nDownload the brochure at: http://www.pharma-microbiology.com/PJwl \nWho Should Attend? \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist Drug Substance External Manufacturer\, Business Development Manager – Testing\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist
URL:https://www.pharmajournalist.com/event/smis-10th-annual-pharmaceutical-microbiology-uk-conference/
LOCATION:London\, UK
ORGANIZER;CN="SMi Group Ltd":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220118
DTEND;VALUE=DATE:20220121
DTSTAMP:20260515T204228
CREATED:20210928T103251Z
LAST-MODIFIED:20210928T103251Z
UID:31764-1642464000-1642723199@www.pharmajournalist.com
SUMMARY:3rd Glioblastoma Drug Development Summit
DESCRIPTION:The 3rd Glioblastoma Drug Development Summit is the only industry led forum for large pharma\, biotech and academic KOLs to unite under the common goal of accelerating the practical translation and clinical development of meaningful therapies for the treatment of glioblastoma. \nThrough investigating the clinical implementation of diverse mechanisms of action\, including\, DNA damage repair\, immunotherapy\, oncolytic viruses\, cholesterol metabolism\, PARP inhibitors and more\, we strive to address the urgent need for novel and much improved treatments for this devastating disease. \nTackling specific drug development challenges such as a better understanding of preclinical efficacy and tolerability data to confidently translate into the clinic\, improving drug delivery across the blood-brain barrier and optimizing clinical trial design to define more measurable outcomes\, this meeting is an absolute must attend for all neuro-oncologists and oncology professionals determined to translate their drug candidates into human clinical trials. \nWith a huge unmet medical need for effective treatments and too many clinical failures to overcome\, there has never been a more important time to attend the 3rd Glioblastoma Drug Development Summit and join your dedicated and determined community to defeat GBM and radically change patients’ lives. \nJoin us as we unite drug developers and academics to tackle unique drug development challenges creating obstacles for effective treatments for GBM patients. \nTo know more visit: https://ter.li/2bmg9q
URL:https://www.pharmajournalist.com/event/3rd-glioblastoma-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR